Carbon nanotube membranes for use in the transdermal treatment of nicotine addiction and opioid withdrawal symptoms

Substance Abuse: Research and Treatment

Volumn 3, Issue 1, 2009, Pages 31-39

  Strasinger, Caroline L ^a   Scheff, Nicole N ^a   Wu, Ji ^b   Hinds, Bruce J ^b   Stinchcomb, Audra L ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Clonidine; Cnt; Nicotine; Transdermal delivery; Variable rate

Indexed keywords

CARBON NANOTUBE; CLONIDINE; NICOTINE; OPIATE; PLACEBO;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG DELIVERY SYSTEM; DRUG TRANSPORT; FEASIBILITY STUDY; HUMAN; INTERMETHOD COMPARISON; IONTOPHORESIS; NICOTINE REPLACEMENT THERAPY; OPIATE ADDICTION; PATIENT COMPLIANCE; SMOKING CESSATION; TOBACCO DEPENDENCE; TRANSDERMAL PATCH; WITHDRAWAL SYNDROME;

EID: 77954208389     PISSN: None     EISSN: 11782218     Source Type: Journal    
DOI: 10.4137/sart.s1050     Document Type: Article

References (26)

1. World Health Organization. The global burden [online]. AccessedMay 30. 2008. www.who.int/substance_abuse/facts/global_burden/en/index.html.
2. Center for Disease Control. Annual smoking-attributable mortality, years of potential life lost, and productivity losses united states,1997-2001.Mmwr. 2005;54:625-8.
3. Wills S. Drugs of abuse. London; Chicago, Pharmaceutical Press. 2005.
4. Gowing L, Farrell M, Ali R, et al. Alpha2 adrenergic agonists for themanagement of opioid withdrawal. Cochrane database of systematicreviews (Online). 2004;CD002024.
5. Oreskovich MR, Saxon AJ, Ellis ML, et al. A double-blind, doubledummy,randomized, prospective pilot study of the partial mu opiateagonist, buprenorphine, for acute detoxifi cation from heroin. Drug andalcohol dependence. 2005;77:71-9.
6. Balfour DJK, Fagerstrom KO. Pharmacology of nicotine and itstherapeutic use in smoking cessation and neurodegenerative disorders.Pharmacology and Therapeutics. 1996;72:51-81.
7. Feyerabend C, Ings RMJ, Russell MAH. Nicotine pharmacokineticsand its application to intake from smoking. British Journal of ClinicalPharmacology. 1985;19:239-247.
8. Brand RM, Guy RH. Iontophoresis of nicotine in-vitro pulsatile drugdeliveryacross the skin. Journal of Controlled Release. 1995;33:285-292.
9. Strain EC, Stitzer ML. The treatment of opioid dependence. Baltimore,Johns Hopkins University Press. 2006.
10. Strasinger CL, Scheff NN, Stinchcomb AL. Prodrugs and codrugs asstratigies for improving percutaneous absorption. Expert Review ofDermatology. 2008;3:221-233.
11. Flynn GL, Stewart B. Percutaneous drug penetration choosingcandidates for transdermal development. Drug Development Research.1988;13:169-185.
12. Chopra N, Hinds B. Catalytic size control of multiwalled carbonnanotube diameter in xylene chemical vapor deposition process.Inorganica Chimica Acta. 2004;357:3920-3926.
13. Majumder M, Chopra N, Andrews R, et al. Nano scale hydrodynamics enhanced flow in carbonnanotubes. Nature. 2005a;438:44-44.
14. Majumder M, Chopra N, Hinds BJ. Effect of tip functionalization ontransport through vertically oriented carbon nanotube membranes.Journal of the American Chemical Society. 2005b;127:9062-9070.
15. Majumder M, Zhan X, Andrews R, et al. Voltage gated carbon nanotubemembranes. Langmuir. 2007;23:8624-8631.
16. Hinds BJ, Chopra N, Rantell T, et al. Aligned multiwalled carbonnanotube membranes. Science. 2004;303:62-65.
17. Lanier RK, Umbricht A, Harrison JA, et al. Evaluation of a transdermalbuprenorphine formulation in opioid detoxification. Addiction(Abingdon, England). 2007;102:1648-56.
18. Huang JF, Sung KC, Hu OYP, et al. The effects of electrically assistedmethods on transdermal delivery of nalbuphine benzoate and sebacoyldinalbuphine ester from solutions and hydrogels. International Journalof Pharmaceutics. 2005;297:162-171.
19. Li GL, Van Steeg TJ, Putter H, et al. Cutaneous side-effects oftransdermal iontophoresis with and without surfactant pretreatment:A single-blinded, randomized controlled trial. British Journal ofDermatology. 2005;153:404-412.
20. Koo PJ. Postoperative pain management with a patient-controlledtransdermal delivery system for fentanyl. Am J Health Syst Pharm.2005;62:1171-6.
21. Drugdex. Clonidine. In: Drugdex system. Thomson Healthcare. 2008.
22. Paudel KS, Nalluri BN, Hammell DC, et al. Transdermal delivery ofnaltrexone and its active metabolite 6-beta-naltrexol in human skin invitro and guinea pigs in vivo. J Pharm Sci. 2005;94:1965-75.
23. Stinchcomb AL, Swaan PW. Transdermal delivery of opioid antagonistprodrigs. IN USPO (Ed.) U.S.A. 2003.
24. Kiptoo PK, Paudel KS, Hammell DC, et al. Transdermal delivery ofbupropion and its active metabolite, hydroxybupropion: A prodrugstrategy as an alternative approach. Journal of Pharmaceutical Sciences. 2008.
25. Banks SL, Pinninti RR, Gill HS, et al. Flux across of microneedletreatedskin is increased by increasing charge of naltrexone and naltrexolin vitro. Pharmaceutical Research. 2008;25:1677-1685.
26. Wermeling DP, Banks SL, Hudson DA, et al. Microneedles permittransdermal delivery of a skin-impermeant medication to humans.Proceedings of the National Academy of Sciences of the United States of America. 2008;105:2058-63.